Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important and under-explored topic, as Fatma et al. present an investigative review examining the potential association […]

Search Results

Showing Results for compounding pharmacies

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Age-related macular degeneration (AMD) is a progressive eye condition that affects millions of people worldwide and poses a significant threat to vision in individuals over the age of 50.1 Of the two types of AMD, wet AMD, which is characterized by ...

Mark CompleteCompleted
BookmarkBookmarked

Mydriasis physiology Mydriasis refers to physiologic or pharmacologic pupillary dilation. Physiologic pupillary dilation occurs naturally as a response to low light and viewing objects in the distance. This process is mediated by both the iris sphincter and the iris dilator ...

Mark CompleteCompleted
BookmarkBookmarked
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri

Biologics have redefined the outcomes of retinal pathologies by targeting the vascular endothelial growth factor (VEGF) pathway. Anti-VEGF therapy has prevented millions of people from going blind due to retinal vascular pathologies.1 Apart from preventing morbidity, it has a widespread ...

Mark CompleteCompleted
BookmarkBookmarked
Ashish Sharma, Baruch D Kuppermann, Anat Loewenstein

A biosimilar is a biologic medical product that is an almost identical copy of an original product manufactured by a different company.1 Biosimilars are officially approved versions of original “innovator” products and can only be manufactured in a well-equipped research ...

Mark CompleteCompleted
BookmarkBookmarked

The introduction of anti-angiogenic agents has revolutionized the treatment of vascular endothelial growth factor (VEGF)-mediated ocular disease. The first anti-angiogenic agent to be approved by the US Food and Drug Administration (FDA), bevacizumab, was originally developed to inhibit tumorigenesis. ...

Close Popup